A Phase 1 interventional study of Oxycodone 40 mg and Tramadol 600 mg in Human Abuse Potential, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Tris Pharma, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.
Among the 2,882 studies in Pain with a site in United States, this one is the 1,735th largest by enrollment of the 2,560 interventional ones that give a count, is one of 94 that started in 2022, is one of 206 in phase 1, and was the 2,338th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 30–75
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 6–17
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,882 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 416 · Phase 3 375 · Phase 4 372
First in 1957; this study’s year is marked. 94 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 66 across the 2,560 interventional studies, 99 across the 299 observational. Of the 2,225 that completed or were terminated, 1,051 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
670 of 2,882 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 7 studies filed under Pain — fewer than ten, so there is no comparison to draw.
172 of the studies in Pain with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000281Phase 3Major Extremity Trauma Research ConsortiumEffect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures | 2026-11-30 |
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2026-12-31 |
Add all 172 to your calendar (.ics) → With an account.
Among the 2,882 studies in Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
Randomized, single site, double-blind, placebo- and active-controlled, crossover, single oral dose, Phase 1 trial, in non dependent recreational opioid users
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo
Drug: Cebranopadol 600 µg
Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo
Drug: Cebranopadol 1000 µg
Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo
Drug: Oxycodone 40 mg
Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets
Drug: Tramadol 600 mg
Single oral dose of 6 capsules containing placebo
Drug: Placebo
Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
Also known as: Qualification Phase/ Treatment Phase
Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
Also known as: Qualification Phase/ Treatment Phase
Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
Also known as: Qualification Phase/ Treatment Phase
Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Also known as: Treatment Phase
Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Also known as: Treatment Phase
Drug Liking Visual analog scale (VAS) Emax
The scale is a 0-100-point scale: 0 = "Strong disliking"; 50 = "Neither like nor dislike"; 100 = "Strong liking"
Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose
VAS rating for Overall Liking
The scale is a 0-100-point scale: 0 = "Strong Disliking", 50 = "Neither Like nor Dislike", 100 = "Strong Liking"
Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose
VAS rating for Take Drug Again
The scale is a 0-100-point scale: 0 = "Definitely would not"; 50 = "Do not care"; 100 = "Definitely would"
Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose
Pupillometry
Data from a series of frames will be used in the calculation, and the final display will show the weighted average and standard deviation of the pupil size. Measurements will be collected under mesopic lighting conditions
Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose
Multi-Tasking Test
Formerly known as the Attention Switching Task (AST), is a test of executive function which provides a measure of the ability to use multiple sources of potentially conflicting information to guide behavior.
Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Jul 2022, 3 months.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 3 months is below that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol